Skip to main content

Table 6 Base-case cost-effectiveness results

From: Cost-effectiveness analysis of ranibizumab for retinal vein occlusion patients in China from the societal perspective

 

BRVO

CRVO

 

Ranibizumab

Laser Photocoagulation

Incremental

Ranibizumab

Observation

Incremental

Total costs

¥87,924

45,952

¥41,971

¥139,407

¥103,163

¥36,244

QALYs

8.954

8.309

0.646

9.480

8.929

0.551

Incremental cost per QALY

  

¥65,008

  

¥65,815

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us